{
    "nctId": "NCT00041067",
    "briefTitle": "S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer",
    "officialTitle": "Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 76,
    "primaryOutcomeMeasure": "Survival at 1 Year",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed stage IV breast cancer\n\n  * Metastasis to the ipsilateral supraclavicular lymph nodes allowed\n* HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting\n* No effusions or ascites as only sites of disease\n* No primary or metastatic brain or central nervous system tumor\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 18 and over\n\nSex:\n\n* Female\n\nMenopausal status:\n\n* Not specified\n\nPerformance status:\n\n* Zubrod 0-2\n\nLife expectancy:\n\n* Not specified\n\nHematopoietic:\n\n* Absolute neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n\nHepatic:\n\n* Bilirubin normal\n* aspartate aminotransferase or Alanine aminotranferease no greater than 1.5 times upper limit of normal (ULN)\n* Alkaline phosphatase no greater than 2.5 times ULN\n\nRenal:\n\n* Not specified\n\nCardiovascular:\n\n* left ventricular ejection fraction normal by multigated radionuclide angiography or echocardiogram (patients who have received prior anthracycline therapy)\n* No clinical evidence or history of cardiomyopathy\n\nOther:\n\n* No pre-existing grade 2 or greater motor or sensory peripheral neuropathy except abnormalities due to cancer\n* No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with Polysorbate 80\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately treated stage I or II cancer currently in complete remission\n* No known sensitivity to E. coli-derived proteins\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* Not specified\n\nChemotherapy:\n\n* At least 6 months since prior chemotherapy\n* Prior anthracycline as adjuvant therapy allowed\n* No prior cumulative dose of doxorubicin more than 360 mg/m\\^2\n* No prior cumulative dose of epirubicin more than 720 mg/m\\^2\n* No more than 1 prior adjuvant or neoadjuvant chemotherapy regimen for primary disease\n* No prior docetaxel\n* No prior vinorelbine\n* Prior paclitaxel allowed\n\nEndocrine therapy:\n\n* Prior hormonal therapy as adjuvant therapy or for metastatic breast cancer allowed\n* No concurrent hormonal therapy\n\nRadiotherapy:\n\n* At least 3 weeks since prior radiotherapy\n\nSurgery:\n\n* At least 2 weeks since prior surgery and recovered",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}